About Myriad Genetics
Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Research Services
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: MYGN
- CUSIP: 62855J10
- Previous Close: $19.05
- 50 Day Moving Average: $16.62
- 200 Day Moving Average: $18.66
- 52-Week Range: $15.15 - $39.74
- Trailing P/E Ratio: 21.53
- Foreward P/E Ratio: 17.80
- P/E Growth: -6.21
- Market Cap: $1.30B
- Outstanding Shares: 68,091,000
- Beta: 0.26
- Net Margins: 8.08%
- Return on Equity: 12.02%
- Return on Assets: 8.35%
Companies Related to Myriad Genetics:
- Debt-to-Equity Ratio: 0.28%
- Current Ratio: 4.13%
- Quick Ratio: 3.51%
What is Myriad Genetics' stock symbol?
Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."
Where is Myriad Genetics' stock going? Where will Myriad Genetics' stock price be in 2017?
13 equities research analysts have issued 1 year target prices for Myriad Genetics' stock. Their forecasts range from $15.00 to $47.00. On average, they anticipate Myriad Genetics' stock price to reach $27.00 in the next twelve months.
When will Myriad Genetics announce their earnings?
Myriad Genetics is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.
Who owns Myriad Genetics stock?
Myriad Genetics' stock is owned by many different of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (14.92%), State Street Corp (5.25%), Frontier Capital Management Co. LLC (4.44%), Renaissance Technologies LLC (3.94%), Dimensional Fund Advisors LP (2.42%) and Disciplined Growth Investors Inc. MN (2.01%). Company insiders that own Myriad Genetics stock include Alexander Ford, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard M Marsh, S Louise Phanstiel and Walter Phd Gilbert.
Who sold Myriad Genetics stock? Who is selling Myriad Genetics stock?
Myriad Genetics' stock was sold by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE, Baillie Gifford & Co., Renaissance Technologies LLC, S&T Bank PA, Marshall Wace LLP, Pinnacle Associates Ltd., Guggenheim Capital LLC and GSA Capital Partners LLP. Company insiders that have sold Myriad Genetics stock in the last year include Alexander Ford, Gary A King and John T Henderson.
Who bought Myriad Genetics stock? Who is buying Myriad Genetics stock?
Myriad Genetics' stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Two Sigma Investments LP, Frontier Capital Management Co. LLC, Senzar Asset Management LLC, State Street Corp, FMR LLC, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main and Dimensional Fund Advisors LP. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, Mark Christopher Capone and Ralph L Mcdade.
How do I buy Myriad Genetics stock?
Shares of Myriad Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Myriad Genetics stock cost?
One share of Myriad Genetics stock can currently be purchased for approximately $19.05.